Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial
1. 系统已在2026-08-31 14:19:05对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
L Gao, H Jiang, H Cai, J Tian, B Shi, W Qiu, C Huang…
JAMA, 2026
jamanetwork.com
Importance Obesity is a worldwide problem and a major public health issue in China. Objective To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of≥ 30). Design, Setting, and Participants A double-blind, placebo-controlled, phase 3, randomized clinical trial including Chinese adults with or without type 2 diabetes that was conducted at 27 hospitals from December 2023 to November 2025 …
